Abbott Laboratories news

   Watch this stock
Showing stories 1 - 10 of about 119   

Articles published

ABT 43.81 +0.03 (0.07%)
price chart
Dividend Aristocrats In Focus Part 41: Abbott Laboratories
Abbott Laboratories (NYSE:ABT) is a diversified health care corporation. The company is a market cap of $66 billion. The company is truly globally diversified, generating nearly 70% of revenues internationally through the first 3 quarters of its fiscal ...
Related articles »  
Abbott Labs to Buy Private Medical Device Company Topera
Abbott Laboratories agreed to acquire privately held medical-device maker Topera Inc. in a deal valued at least $250 million that would add a developer of catheter-based electrophysiology technologies to its portfolio.
Abbott Labs to buy Menlo Park's Topera for $250M  Silicon Valley Business Journal
Abbott Labs to buy medical device company Topera  Chicago Business Journal
Related articles »  
How Abbott Laboratories used Silicon Valley's playbook to build a better ...
Abbott Vascular Inc., a Santa Clara-based division of 69,000-employee Abbott Labs (NYSE: ABT), wanted a kind of scaffold that could open arteries that carry blood away from the heart.
Abbott Laboratories (ABT), AbbVie Inc (ABBV): Biotech Stocks Set To Surge
biotechnology William Patalon III: When I earned my MBA from the Rochester Institute of Technology (RIT) back in the mid-1990s, my focus was finance and investing.
Abbott Labs Pays $250 Million for Topera in Heart Health Move
Abbott Laboratories (ABT) entered the heart rhythm disorder market on Wednesday with the purchase of Topera Inc. as well as the option to buy Advanced Cardiac Therapeutics (ACT) .
Abbott Secures Two Catheter-Based Medical Device Companies  Med Device Online (press release)
Related articles »  
Valuation analysis for Abbott Laboratories (NYSE:ABT)
Pursuing our interest in fair valuation our attention then turns to the PE multiple, and the PE multiple for Abbott labs skyrocketed after the spinoff.
Deutsche Bank Upgrades Abbott Laboratories
Moreover, "We believe Abbott can sustain mid-to-high single digit sales growth and 10%-12% EPS growth. Given this, its balance sheet and cash flows, we believe the stock should trade at a premium valuation and there is significant upside from< current ...
Abbott Laboratories's Neutral Rating Reaffirmed at Zacks (ABT)  Ticker Report
Related articles »  
Abbott Laboratories Shares Cross 2% Yield Mark
Looking at the universe of stocks we cover at Dividend Channel, in trading on Wednesday, shares of Abbott Laboratories ABT +0.07% (NYSE: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.88), with the stock ...
Abbott Laboratories Reaches New 1-Year High at $44.63 (ABT)  WKRB News
News Buzz � Harley-Davidson, Inc. (NYSE:HOG), Abbott Laboratories (NYSE ...  Techsonian (press release)
Related articles »  
Abbott Laboratories (ABT) Showing Signs Of Being Water-Logged And Getting ...
Trade-Ideas LLC identified Abbott Laboratories ( ABT) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate.
Abbott Laboratories Assigned "AA-" Credit Rating (ABT)  Intercooler
Related articles »  
Accenture Now #65 Largest Company, Surpassing Abbott Laboratories
But comparing market capitalization (factoring in those share counts) creates a true �apples-to-apples� comparison of the value of two stocks.